SAN FRANCISCO,
May 29, 2019 /PRNewswire/ --
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based
genetic medicines company focused on developing and commercializing
innovative products for serious rare neuromuscular diseases, today
announced that it has appointed Edward R.
Conner, M.D. as Senior Vice President and Chief Medical
Officer and promoted Fulvio Mavilio,
Ph.D. to Senior Vice President of Translational Science. Dr.
Suyash Prasad, Senior Vice President
and Chief Medical Officer and Dr. John
Gray, Senior Vice President and Chief Technology Officer are
leaving Audentes.
"We are delighted to welcome Ed and Fulvio to our senior
leadership team," stated Matthew R.
Patterson, Chairman and Chief Executive Officer. "Each
is a recognized industry leader with a demonstrated track-record in
the development of novel gene therapy products targeting rare
diseases, and we look forward to their contributions as we progress
AT132 for the treatment of XLMTM towards regulatory submissions,
and advance our Pompe, Duchenne muscular dystrophy, and myotonic
dystrophy programs into clinical development. I would also
like to thank Suyash and John for their numerous important
contributions to Audentes."
As Senior Vice President and Chief Medical Officer, Ed
will be responsible for leading the global clinical development
strategy for Audentes. He will oversee clinical development,
clinical operations, regulatory affairs, medical affairs and
patient advocacy. Ed's appointment is effective July 15, 2019. In Fulvio's new role
as Senior Vice President of Translational
Science, he is responsible for advancing the company's
pipeline from discovery through to IND-enabling preclinical
development. Fulvio oversees the molecular biology, in vivo
pharmacology, bioinformatics and bioanalytics functions.
Ed joins Audentes from Sangamo Therapeutics, Inc.
where he served as Senior Vice President and Chief Medical
Officer and led the clinical development of the company's pipeline
of genomic therapies. Prior to Sangamo, Ed
served as Vice President, Global Clinical Development at Ultragenyx
Pharmaceutical Inc., where he led the global clinical development
efforts for two of the company's rare disease product
candidates. Prior to Ultragenyx, Ed served as Senior Medical
Director at BioMarin Pharmaceutical Inc., where he led clinical
development and regulatory interactions for its global Phase 3
program in Pompe disease, and earlier in his career Ed served as
Medical Director at Genentech, Inc. where he was the clinical
science team leader of two product candidates, including
XOLAIR®. Ed completed his Internal Medicine residency
training at the University of Michigan
and was a fellow in Clinical Immunology and Allergic Diseases at
Johns Hopkins School of Medicine. He earned a B.S. in
Biology, cum laude, from Duke
University and his M.D. from the University of California, San Francisco.
Fulvio is a highly regarded, world-leading expert and
pioneer in the gene therapy field. He has designed and
developed gene therapies for inherited and acquired diseases,
including the first ever commercially approved ex vivo gene
therapy, Strimvelis®.
Fulvio joined Audentes in 2017 from Genethon where he served as
Chief Scientific Officer and led the development of a robust
pipeline of gene therapy programs, including the initial discovery
work for AT132. Prior to Genethon, Fulvio was co-Director of
the Center for Regenerative Medicine of the University of Modena,
Director of Discovery of Molmed SpA, founder and Chief Scientific
Officer of Genera SpA, and co-Director of the San Raffaele-Telethon
Institute of Gene Therapy. Fulvio serves as Professor of
Molecular Biology at the University of Modena and Reggio
Emilia. He earned an undergraduate degree in Biology at the
University of Rome and a Ph.D. in
Medical Genetics at the University of Rome School of
Medicine.
About Audentes Therapeutics,
Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a
leading AAV-based genetic medicines company focused on developing
and commercializing innovative products for serious rare
neuromuscular diseases. We are leveraging our AAV gene
therapy technology platform and proprietary manufacturing expertise
to develop programs across three modalities: gene replacement,
vectorized exon skipping, and vectorized RNA knockdown. Our
product candidates are showing promising therapeutic profiles in
clinical and preclinical studies across a range of neuromuscular
diseases. Audentes is a focused, experienced and passionate
team driven by the goal of improving the lives of
patients.
For more information regarding Audentes, please visit
www.audentestx.com.
Forward Looking Statements
This press release
contains forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, the timing and nature of
the company's research and development activities. All statements
other than statements of historical fact are statements that could
be deemed forward-looking statements. Although the company believes
that the expectations reflected in such forward-looking statements
are reasonable, the company cannot guarantee future events,
results, actions, levels of activity, performance or achievements,
and the timing and results of biotechnology development and
potential regulatory approval is inherently uncertain.
Forward-looking statements are subject to risks and uncertainties
that may cause the company's actual activities or results to differ
significantly from those expressed in any forward-looking
statement, including risks and uncertainties related to the
company's ability to advance its product candidates, obtain
regulatory approval of and ultimately commercialize its product
candidates, the timing and results of preclinical and clinical
trials, the company's ability to fund development activities and
achieve development goals, establish and scale-up manufacturing
processes that comply with regulatory requirements, and protect
intellectual property and other risks and uncertainties described
under the heading "Risk Factors" in documents the company files
from time to time with the Securities and Exchange Commission.
These forward-looking statements speak only as of the date of this
press release, and the company undertakes no obligation to revise
or update any forward-looking statements to reflect events or
circumstances after the date hereof.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contacts:
Sarah
Spencer
415.957.2020
sspencer@audentestx.com
Katie Hogan
415.951.3398
khogan@audentestx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-announces-changes-to-senior-management-team-300858527.html
SOURCE Audentes Therapeutics, Inc.